BiomX is developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as cystic fibrosis, inflammatory bowel disease, atopic dermatitis and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.
קישור חיצוני עבור BiomX Inc
7 Pinhas Sapir St.
Ness Ziona, 7403635,, IL
Join Urania Rappo, MD, today for insights on overcoming enrollment challenges in rare disease trials. #ClinicalTrials #RareDisease #Phage
Struggling with rare disease trial enrollment? Join Urania Rappo, MD, #BiomX and Caitlin Hirschman, Rho, at #OCT NE on October 23 at 2:30 Eastern as they share how they over-enrolled, meeting on-time enrollment goals. Don’t miss it!
Thank you, Cystic Fibrosis Foundation, for your trust and support! We are honored to work together in advancing innovative treatments for cystic fibrosis patients.
We have invested an additional $5 million in BiomX to support a Phase 2b clinical trial to test the effectiveness of its bacteriophage (phage) therapy in treating chronic Pseudomonas aeruginosa infections — the second most common type of lung infection in people with cystic fibrosis. Phage therapy uses phages (bacteria-specific viruses) to kill specific bacterial strains that are causing an infection. “We continue to look for innovative ways to treat chronic and drug-resistant infections in people with CF,” said Tiffany Burnett, senior director of biopharma programs at the Cystic Fibrosis Foundation. “These types of trials are important as we seek to move past individual reports of success to determine whether phage therapy is a viable treatment option for the broader CF population.”
Following our last announcement, we're thrilled to share that we’ve officially closed the acquisition of Adaptive Phage Therapeutics and the concurrent $50 million financing round. This strategic move positions us as a leading phage therapy company, with an advanced pipeline featuring two Phase 2 assets: BX004 for the treatment of chronic pulmonary infections in cystic fibrosis patients and BX211 for diabetic foot osteomyelitis. The $50 million financing will be used to advance these two lead product candidates through Phase 2 clinical readouts in 2025, marking significant progress in our mission to advance phage-based therapies. We're grateful for the continued support of our investors and community. For more details, check out the official press release: https://lnkd.in/dcsX8V9w #BiomX #PhageTherapy #Biotech
Exciting News! 🎉🎉 We are thrilled to announce our entry into a merger agreement with Adaptive Phage Therapeutics, Inc. (APT), along with a concurrent $50 million financing deal This strategic move will establish a company with world-class science and innovation aimed at harnessing the extraordinary potential of phage to treat serious infectious diseases and will position us as a leading phage therapy company with a robust pipeline. Join us for a conference call today at 9:00 a.m. EDT for more insights into this exciting development. Read the full PR: https://lnkd.in/devJqnmu
🌟 We are thrilled to announce that BX004 has received Orphan Drug Designation from the FDA for treating chronic pulmonary infection in cystic fibrosis patients. This recognition highlights the urgency to innovate treatments for this patient group. 💪 Check out the news here: https://lnkd.in/dCQp3B7f #BiomX #BX004 #CysticFibrosis
BiomX Inc פרסם מחדש את זה
Phage therapy researcher at KU Leuven | Science communicator and patient advocate | Follow @MotherofPhage
This Friday we have a very exciting Phage Phriday! We welcome Iddo Weiner from BiomX Inc who will speak about new phase 1b/2a clinical trial results for #cysticfibrosis. Also we welcome Amanda (Curtis) Burkardt from PHIOGEN, an exciting new #phage company developing therapies to combat life-threatening infections. We also welcome all former guests to join us for this special podcast. Phage Phriday with hosts Jean-Paul Pirnay, Adriana Carolina Hernandez Morales and Sabrina Green. https://lnkd.in/emnw4xZS hey - you should join us Dec 22, 9:00 pm for Phage Phriday Holiday Special.
Join us today at 12 noon
Join BiomX Inc (#PHGE) for virtual KOL event TOMORROW at 12p ET featuring Dr. Eitan Kerem, M.D. (Hadassah University Medical Center) and Dr. Robert T. “Chip” Schooley, M.D. (University of California, San Diego), who will review the positive results from part 2 of Phase 1b/2a Trial of BX004 in cystic fibrosis patients with Chronic Pseudomonas aeruginosa Infections. Register here: https://brnw.ch/21wEZfW
Save the date! We are hosting a virtual Key Opinion Leader (KOL) Event on December 4, 2023, at 12:00 PM ET to delve into the positive results from Part 2 of the Phase 1b/2a trial of BX004 in CF patients. 🤝 Join renowned experts Dr. Eitan Kerem, M.D., and Dr. Robert T. "Chip" Schooley, M.D., for insights into phage therapy, the CF treatment landscape, and the unmet medical need. 📊 Jonathan Solomon, CEO of BiomX, will review the topline results. To register, click here: https://lnkd.in/dPzFZxBK #BiomX #BX004 #CysticFibrosis #ClinicalTrial
Jonathan Solomon wrote so nice, I had to share his words
🎉 Exciting News! We are thrilled to announce positive topline results from Part 2 of our BX004 trial for treating chronic pulmonary infections in Cystic Fibrosis patients. This marks a significant milestone in our commitment to advancing breakthrough solutions. 🔗 Access the full details directly through the official press release: https://lnkd.in/dq_gd9FW Join our webcast today at 9:00 am ET for an in-depth discussion, and mark your calendar for the Key Opinion Leader (KOL) event on December 4, 2023, at 12:00 pm ET. A big thank you to our incredible team for their hard work and dedication! 💪👏 #BiomX #BX004 #CysticFibrosis #ClinicalTrialSuccess
🎉 Exciting News! We are thrilled to announce positive topline results from Part 2 of our BX004 trial for treating chronic pulmonary infections in Cystic Fibrosis patients. This marks a significant milestone in our commitment to advancing breakthrough solutions. 🔗 Access the full details directly through the official press release: https://lnkd.in/dq_gd9FW Join our webcast today at 9:00 am ET for an in-depth discussion, and mark your calendar for the Key Opinion Leader (KOL) event on December 4, 2023, at 12:00 pm ET. A big thank you to our incredible team for their hard work and dedication! 💪👏 #BiomX #BX004 #CysticFibrosis #ClinicalTrialSuccess